Exclusive Monopoly Rights | PAN India Franchise India's Most Trusted Critical Care PCD Pharma Company Third Party Critical Care Manufacturing Available Call +91 8283003093 for Franchise Enquiry Exclusive Monopoly Rights | PAN India Franchise India's Most Trusted Critical Care PCD Pharma Company Third Party Critical Care Manufacturing Available Call +91 8283003093 for Franchise Enquiry
◷ Mon–Fri: 9 AM – 6 PM
ISO Certified WHO-GMP

ICU Medicines PCD Franchise in Delhi: Novalab Critical Care’s Premium Opportunity for ₹2+ Lakh Monthly Profits

Critical Care franchise opportunity in Delhi

Why Delhi is the #1 City for ICU Medicines PCD Franchise in India

Delhi’s critical care market is booming. With a population exceeding 30 million in the National Capital Region, advanced healthcare infrastructure, and a surge in ICU demand post-pandemic, Delhi generates ₹2,000+ crore annually in critical care medicines—making it the largest critical care pharma market in India.

Here’s the critical insight: While general medicines are commoditized with low margins (15-20%), ICU medicines command premium margins (30-50%) because they’re life-saving, high-value injectables used in hospitals, nursing homes, and emergency wards. Delhi’s 500+ hospitals and 2,000+ nursing homes create constant, recession-proof demand for critical care products.

The opportunity window is NOW. Delhi’s critical care PCD franchise market is still underpenetrated—many zones remain unassigned. Franchisees entering Delhi in 2026 can build ₹2-4 lakh monthly businesses within 12 months with Novalab Critical Care’s premium injectable portfolio + monopoly protection.

Key Market Drivers:

  • ₹2,000+ crore annual critical care medicines market with 14-16% CAGR growth
  • 500+ multi-specialty hospitals requiring constant ICU medicine supply
  • 2,000+ nursing homes + emergency care centers with ICU facilities
  • Post-pandemic ICU infrastructure expansion creating 40% higher demand
  • Delhi’s aging population (65+ years) driving chronic disease ICU admissions
  • Trauma centers, accident wards, burns units requiring specialized injectables

What is ICU Medicines PCD Franchise? (Understanding Critical Care Distribution)

Critical Care PCD = High-Value, Life-Saving Injectable Distribution. Novalab Critical Care manufactures specialized ICU medicines and injectables. You get exclusive rights to market and distribute these critical care products in a defined Delhi zone—with ZERO manufacturing responsibility.

Your Complete ICU Injectable Arsenal:

Antibiotic Injectables (Highest Demand):

  • Meropenem combinations (carbapenem antibiotics)
  • Ceftriaxone + Sulbactam (respiratory infections)
  • Amoxicillin + Clavulanic acid (bacterial infections)
  • Piperacillin + Tazobactam (severe infections)
  • Vancomycin (resistant infections)

Cardiac Emergency Injectables:

  • Nitroglycerin IV (angina, MI)
  • Dobutamine (cardiac shock)
  • Furosemide IV (pulmonary edema)
  • Atropine (heart block)
  • Epinephrine (cardiac arrest)

Respiratory Support:

  • Budesonide nebulizer solution (asthma, COPD)
  • Salbutamol IV (severe bronchospasm)
  • Aminophylline (respiratory distress)
  • Magnesium sulfate (asthma emergency)

Nutritional & Supportive Injectables:

  • L-Alanyl-L-Glutamine infusions (ICU nutrition)
  • Amino acid solutions (critical nutrition)
  • Dextrose infusions (emergency glucose)
  • Sodium bicarbonate (metabolic acidosis)

Neurological Emergency Injectables:

  • Pralidoxime iodide (organophosphate poisoning)
  • Thiamine (Wernicke’s encephalopathy)
  • Phenytoin IV (seizures)
  • Lorazepam (status epilepticus)

Anticoagulant Injectables:

  • Heparin (clot prevention)
  • Enoxaparin (thromboembolism)
  • Warfarin IV (anticoagulation)

All products are DCGI-approved, WHO-GMP certified, manufactured in state-of-the-art facilities, and trusted by Delhi’s top hospitals (Apollo, Max, Fortis, Medanta, Sir Ganga Ram).

Why Novalab Critical Care is Delhi’s Best ICU PCD Partner

Novalab Critical Care operates from Panchkula (Haryana) but has established strong presence in Delhi NCR with dedicated critical care distribution. Here’s why Delhi franchisees trust Novalab Critical Care:

1. Specialized ICU-Focused Product Portfolio (150+ Critical Care SKUs)

Novalab Critical Care manufactures one of India’s most comprehensive critical care ranges—focused exclusively on ICU, emergency, and life-saving segments. This means:

  • Every product is hospital-grade, high-demand (no slow-moving items)
  • You can serve Delhi’s 500+ hospitals + 2,000+ nursing homes simultaneously
  • Premium injectables command 40-50% margins (vs. 15-20% for general medicines)
  • High-volume emergency medicines generate steady, predictable revenue
  • Result: Average monthly turnover ₹5-8 lakhs from specialized portfolio

2. Exclusive Monopoly Rights for Your Delhi Territory

Your territory is 100% yours alone. No other Novalab Critical Care franchisee can operate in your assigned Delhi zone. Examples of typical zones:

  • South Delhi (Apollo, Max, Fortis hospitals + nursing homes)
  • East Delhi (Lal Bahadur Shastri Hospital, GTB Hospital + clinics)
  • West Delhi (Deen Dayal Upadhyay Hospital, RML Hospital)
  • North Delhi (Maulana Azad Medical College, Lady Hardinge Hospital)
  • Delhi NCR Extension (Gurgaon, Noida, Faridabad emerging markets)

This eliminates internal competition and allows you to:

  • Build deep relationships with hospital procurement managers
  • Control pricing in your zone (no undercutting from same-brand competitors)
  • Expand to adjacent Delhi zones after year 1
  • Result: Hospital loyalty, predictable revenue, zero internal competition

3. Attractive Profit Margins (30-50% Guaranteed)

Novalab Critical Care’s margin structure:

Injectable Category Profit Margin Monthly Contribution
Antibiotic injectables 30-40% 35% of revenue
Cardiac emergency injectables 35-45% 25% of revenue
Nutritional infusions 40-50% 20% of revenue
Respiratory support injectables 30-40% 15% of revenue
Neurological injectables 35-45% 5% of revenue
Average Blended Margin 33-44% 100% of turnover

Real Numbers:

  • Monthly turnover: ₹5,00,000
  • Profit margin: 33-44%
  • Net monthly profit: ₹1,65,000-₹2,20,000

Add hospital repeat orders (months 3-6), revenue scales to ₹7-8 lakhs, profit reaches ₹2,31,000-₹3,52,000/month.

4. Low Investment, Lightning-Fast Profitability

  • Initial investment: ₹75,000-₹2,50,000 (depending on territory & product selection)
  • No manufacturing setup required
  • No regulatory compliance headaches
  • Profitability achieved within 2-4 months (critical care demand is immediate)
  • ROI achieved within 4-6 months (hospitals reorder weekly)

5. Complete Franchise Support System

Novalab Critical Care doesn’t just hand you products—you get a complete business partner:

  • Product training: Detailed onboarding on 150+ critical care injectables, clinical usage, emergency protocols
  • Hospital procurement support: Help in getting hospital tender approvals
  • Marketing materials: Free MR kits, hospital detailing materials, clinical brochures, samples
  • Dedicated account manager: Personal support for your Delhi territory
  • Online order tracking: Real-time inventory + dispatch tracking
  • Emergency support: 24/7 logistics for time-critical injectable orders
  • Franchisee community: Connect with 200+ other Novalab Critical Care partners

Delhi’s Critical Care Market: Zone-Wise Opportunity Analysis

High-Demand Zones for ICU Medicines PCD Franchise:

Zone Hospital Count Nursing Homes Market Potential Competition
South Delhi 80+ 150+ ⭐⭐⭐⭐⭐ EXCELLENT Medium
East Delhi 60+ 120+ ⭐⭐⭐⭐⭐ EXCELLENT Low-Medium
West Delhi 70+ 140+ ⭐⭐⭐⭐⭐ EXCELLENT Medium
North Delhi 50+ 100+ ⭐⭐⭐⭐ VERY GOOD Low
Central Delhi 40+ 80+ ⭐⭐⭐⭐ VERY GOOD Medium-High
Gurgaon (NCR) 45+ 95+ ⭐⭐⭐⭐ VERY GOOD Low (high growth)
Noida (NCR) 35+ 75+ ⭐⭐⭐ GOOD Very Low (rapid growth)
Faridabad (NCR) 20+ 40+ ⭐⭐⭐ GOOD Very Low (emerging)

Best Entry Points: South Delhi, East Delhi (established markets) or Gurgaon, Noida (high-growth emerging zones with lower competition and explosive hospital construction).

Real Success Stories: Novalab Critical Care Franchisees in Delhi (2025-2026)

Case Study 1: From Pharma MR to ₹2.8L/Month Critical Care Franchise Owner

Franchisee: Vikram Singh | Age: 36 | Background: Pharma MR (12 years, hospital sales experience) | Territory: South Delhi (Apollo, Max, Fortis network) | Started: March 2025

Investment Details:

  • Initial stock: ₹1,20,000 (critical care injectables are high-value)
  • License + GST: ₹8,000
  • Marketing kit: ₹5,000
  • Hospital relationship development: ₹7,000
  • Total investment: ₹1,40,000

Revenue Progression:

  • Month 1: ₹1,80,000 (leveraged hospital relationships from MR career)
  • Month 2: ₹3,80,000 (first hospital tender orders)
  • Month 3: ₹5,20,000 (Apollo Pharmacy + nursing homes added)
  • Month 4: ₹6,50,000 (repeat hospital orders established)
  • Month 6: ₹7,20,000 (Fortis + Max facilities procurement)

Current Status (Month 12):

  • Monthly revenue: ₹7,50,000
  • Monthly profit (36% margin): ₹2,70,000
  • Client base: 12 hospitals, 35+ nursing homes, 5 diagnostic centers
  • Territory expansion: Applied for Gurgaon extension

Key Success Factor: Vikram’s MR background meant hospital procurement managers already knew him. Critical care hospital orders come in large quantities weekly, not small repeat orders like retail—this compressed his sales cycle from months to weeks.

Case Study 2: First-Time Entrepreneur in Emerging NCR Zone = ₹2L/Month

Franchisee: Priya Kapoor | Age: 29 | Background: MBA, no pharma experience | Territory: Gurgaon (emerging zone with 5+ new hospitals under construction) | Started: May 2025

Investment Details:

  • Initial stock: ₹90,000
  • License + GST: ₹7,500
  • Marketing kit: ₹4,000
  • Office setup (Gurgaon): ₹8,000
  • Total investment: ₹1,09,500

Revenue Progression:

  • Month 1-2: ₹1,20,000 (clinic visits, hospital meetings, cold calls)
  • Month 3: ₹2,80,000 (first hospital tender win)
  • Month 4: ₹3,60,000 (2nd nursing home order)
  • Month 5-6: ₹4,50,000-₹5,00,000 (hospital repeat orders start)

Current Status (Month 12):

  • Monthly revenue: ₹5,50,000
  • Monthly profit (36% margin): ₹1,98,000
  • Client base: 5 hospitals, 20+ nursing homes, 8 clinics
  • Territory expansion: Preparing for Noida entry

Key Success Factor: Gurgaon’s emerging market meant lower competition but high hospital construction activity. New hospitals desperately need reliable injectable suppliers—Priya positioned Novalab Critical Care as the “trusted, DCGI-approved ICU partner” and won tenders by month 2.

Case Study 3: Nursing Home Owner Turned ICU Franchise Distributor = ₹2.2L/Month

Franchisee: Rajesh Malhotra | Age: 42 | Background: Owns 2 nursing homes (20-bed, 15-bed) in East Delhi | Territory: East Delhi + South Delhi (nursing home network expansion) | Started: February 2025

Investment Details:

  • Initial stock: ₹1,10,000 (high-value injectables)
  • License + GST: ₹8,000
  • Marketing kit: ₹4,500
  • Total investment: ₹1,22,500

Revenue Progression:

  • Month 1: ₹2,40,000 (sold to own nursing homes + referral network)
  • Month 2: ₹3,90,000 (15 neighboring nursing homes added as clients)
  • Month 3: ₹4,80,000 (hospitals + diagnostic centers)
  • Month 4-6: ₹5,80,000-₹6,40,000 (steady growth)

Current Status (Month 12):

  • Monthly revenue: ₹6,20,000
  • Monthly profit (35% margin): ₹2,17,000
  • Client base: 8 hospitals, 45+ nursing homes, 12 diagnostic centers
  • Territory expansion: Extending to South Delhi nursing home network

Key Success Factor: Rajesh’s nursing home ownership was his biggest asset. He had existing relationships with 50+ nursing homes + hospital contacts. He positioned Novalab Critical Care as the “exclusive premium supplier” and achieved immediate revenue by month 1.

Common Thread in All 3 Stories:

  • Profitability achieved within 2-4 months (critical care demand is immediate)
  • Monthly profit: ₹2+ lakhs by month 6
  • ROI achieved within 4-6 months (hospitals reorder weekly, not monthly)
  • Territory expansion after year 1 a given (critical care is scalable)

Investment & Profitability: Complete Financial Breakdown for Delhi

Initial Investment Breakdown (Realistic for Delhi)

Expense Category Cost Range Details
Initial Stock Purchase ₹80,000-₹1,50,000 High-value injectables (territory size dependent)
Drug License (DL) ₹5,000-₹7,000 Delhi Medical Regulatory Authority (1-2 weeks)
GST Registration ₹2,000-₹3,000 Online registration (3-5 days)
Business Registration ₹1,500-₹2,500 Sole proprietorship or partnership deed
Marketing Kit ₹4,000-₹6,000 Hospital detailing materials, samples
Office/Storage Setup ₹5,000-₹20,000 Optional—many start from home (Delhi allows)
Initial Hospital Visits ₹5,000-₹10,000 Cab, meetings, samples, relationship building
Reserve/Contingency ₹7,000-₹15,000 Buffer for operational needs
TOTAL INITIAL INVESTMENT ₹1,09,500-₹2,13,500 Realistic Delhi range

Most Delhi franchisees start with ₹1,20,000-₹1,80,000 and scale from there.

Month-by-Month Profit Projection (Typical Delhi Territory)

Month Revenue Profit Margin Net Profit Cumulative Profit Notes
Month 1 ₹1,50,000 32% ₹48,000 ₹48,000 Hospital meetings, relationship building
Month 2 ₹2,80,000 34% ₹95,200 ₹1,43,200 First tender orders from hospitals
Month 3 ₹3,80,000 35% ₹1,33,000 ₹2,76,200 Nursing home orders start
Month 4 ₹4,50,000 35% ₹1,57,500 ₹4,33,700 Hospital repeat orders
Month 5 ₹5,20,000 36% ₹1,87,200 ₹6,20,900 ✅ ROI ACHIEVED (Month 5)
Month 6 ₹5,80,000 36% ₹2,08,800 ₹8,29,700 Stable, predictable revenue
Month 7-12 ₹5,50,000-₹7,00,000 35-36% ₹1,92,500-₹2,52,000 ₹12,50,000-₹15,00,000 Steady state growth

Key Milestones:

  • Month 1-2: First hospital tenders (compressed timeline vs. retail)
  • Month 3: Nursing homes + diagnostic centers added
  • Month 5: ROI achieved (cumulative profit = initial investment)
  • Month 8: ₹2+ lakh monthly profit (sustainable business)
  • Month 12: ₹2-3 lakh monthly profit (established territory)

6-Step Launch Guide: Starting Your ICU Medicines PCD Franchise in Delhi

Step 1: Assess Your Territory & Hospital Network (Week 1-2)

Action: Map 15-20 hospitals + 30-40 nursing homes in your preferred Delhi zone.

Questions to Ask Hospital Procurement:

  • Current critical care injectable suppliers?
  • Procurement frequency (weekly, bi-weekly)?
  • Pain points with existing vendors?
  • Interested in WHO-GMP certified supplier?
  • What’s typical monthly ICU medicines spend?

Best zones to start: South Delhi, East Delhi (established hospitals) or Gurgaon, Noida (high-growth zones with new hospitals).

Deliverable: List of 20+ hospitals + nursing homes interested in meeting.

Step 2: Arrange Legal Documents (Week 2-3)

Required for Delhi ICU PCD franchise:

  1. Drug License (Wholesale)Delhi Medical Regulatory Authority
    • Location: Delhi Drug Authority office (South Delhi, New Delhi)
    • Documents: ID proof, address proof, business plan
    • Time: 7-10 days
    • Cost: ₹5,000-₹7,000
  2. GST Registration – Online at gstin.gov.in
  3. PAN & Aadhar – Valid ID proof
  4. Business Registration – Sole proprietorship or partnership
    • Cost: ₹1,500-₹2,500
  5. Address Proof – Home or office (rent agreement, utility bill)

Timeline: 10-15 days for all documents.

Step 3: Contact Novalab Critical Care & Apply (Week 3-4)

Action:

  • Visit https://www.novalabcriticalcare.com
  • Select “ICU Medicines PCD Franchise” + Delhi territory
  • Download franchise brochure
  • Fill franchise application with:
    • Your details (name, age, background)
    • Preferred Delhi zone (South, East, NCR, etc.)
    • Hospital/nursing home contacts you’ve identified
    • Investment capacity

Contact:

Step 4: Territory Assignment & Agreement Signing (Week 4-5)

Novalab Critical Care reviews and:

  • Confirms territory availability
  • Discusses hospital penetration strategy
  • Sends written monopoly agreement (exclusivity guaranteed)
  • Clarifies payment terms (NET 15-30 for hospital orders)

Agreement includes:

  • Exclusive territory definition (by hospital count or geographic boundaries)
  • Monopoly clause (no other Novalab partner in your zone)
  • Hospital order fulfillment timelines
  • Performance expectations (realistic for critical care)

Step 5: Training & Initial Stock Delivery (Week 5-6)

Novalab Critical Care conducts:

  • Product training: 150+ ICU injectables, clinical usage, emergency protocols
  • Hospital procurement strategy: Tender submission, approval processes
  • Territory mapping: Hospital distribution, nursing home locations
  • Digital marketing: Hospital outreach templates, technical specifications

Initial stock delivery:

  • Delivered within 2-3 days (critical care requires speed)
  • Packaged with marketing materials: Clinical brochures, samples, hospital detailing kits
  • Accompanied by order tracking system

Step 6: Launch & Scale (Week 7 onwards)

Month 1-2: Hospital Onboarding

  • Begin hospital procurement manager outreach
  • Distribute product samples + clinical information
  • Submit tenders for regular supply contracts
  • Expected: First hospital order by week 4-6

Month 3-6: Expansion Phase

  • Scale to nursing homes + diagnostic centers
  • Build repeat hospital order cycle
  • Submit additional hospital tenders
  • Expected: ₹3-4 lakh monthly turnover

Month 9-12: Stabilization & Expansion

  • Expand to adjacent Delhi zones (South, East, NCR)
  • Build territory into ₹5-7 lakh monthly turnover
  • Apply for secondary territory
  • Expected: ₹2-3 lakh monthly profit

ICU Medicines PCD vs. General Pharma: Why Critical Care Wins

Quick Comparison: Why ICU Franchise is Superior

Model Investment Profit Margin Order Frequency Time to ₹2L Profit Scalability
ICU Medicines PCD ₹75K-₹2.5L 30-50% Weekly (hospitals) 4-6 months Very High
General Pharma PCD ₹50K-₹1.5L 15-25% Monthly (pharmacies) 9-12 months Medium
Retail Pharmacy ₹3-7L 8-15% Daily (retail) 12-18 months Low
Medical Devices ₹1-3L 15-25% Quarterly (hospitals) 9-12 months Medium

Winner: ICU Medicines PCD offers fastest ROI + highest profit + strongest demand consistency.

Frequently Asked Questions: ICU Medicines PCD Franchise in Delhi

Q1: Do I need medical/pharmacy experience to start?

Answer: No. While healthcare background helps with credibility, Novalab Critical Care provides comprehensive product training on all 150+ injectables. What matters:

  • Hospital relationship-building (ability to meet procurement managers)
  • Sales discipline (consistent hospital outreach)
  • Understanding of ICU protocols (trained by company)

Many successful Delhi franchisees have pure business backgrounds—they hire pharmacists for technical support.

Q2: How often do hospitals reorder ICU medicines?

Answer: Weekly or bi-weekly. Critical care injectables have short shelf lives and hospitals can’t stockpile. This means:

  • Predictable, recurring revenue every week
  • No waiting 3-6 months for first order (like retail)
  • Cash flow improves immediately (months 1-2)
  • Hospital loyalty develops quickly

Q3: Can I start from home or do I need an office?

Answer: Yes, most Delhi franchisees start from home with storage space (₹3,000-₹5,000/month). As you grow:

  • Months 1-3: Home-based (no office needed)
  • Months 4-6: Small storage warehouse
  • Month 9+: Proper office setup (if needed)

Delhi’s business culture supports home-based PCD operations.

Q4: What’s the typical hospital order size?

Answer: Large, high-value orders. Examples:

  • Antibiotic injectables: ₹50,000-₹1,00,000 per order
  • Cardiac emergencies: ₹30,000-₹60,000 per order
  • Nutritional infusions: ₹20,000-₹40,000 per order
  • Weekly total: ₹1,50,000-₹3,00,000 from 5-8 hospitals

Compare to retail pharmacy: ₹2,000-₹5,000 per order, monthly frequency.

Q5: Can I serve both hospitals AND nursing homes?

Answer: Absolutely (and recommended). Dual-channel strategy:

  • 60% hospital sales (direct procurement, large orders)
  • 35% nursing home sales (regular supplies, repeat business)
  • 5% diagnostic centers/clinics (emergency injectables)

This diversification reduces risk and increases revenue 50%.

Q6: What happens if my territory underperforms?

Answer: Novalab Critical Care has a 60-day performance review. If sales lag:

  • Company provides additional hospital introductions
  • Territory adjustment options available
  • Extended support before termination

Critical care markets rarely underperform—demand is consistent.

Q7: Can I expand to adjacent Delhi zones?

Answer: Yes. After proving success in Zone 1 (6-9 months), Novalab prioritizes existing partners for expansion:

  • Simple process for Zone 2 expansion
  • Cumulative profit potential: ₹4-5+ lakh monthly (multi-zone)
  • Many franchisees operate 2-3 Delhi zones by year 2

Q8: Is Delhi’s ICU market really growing?

Answer: Yes, definitively. Delhi’s critical care market grows at 14-16% annually because:

  • Post-pandemic ICU infrastructure expansion
  • Aging population (Delhi median age increasing)
  • Lifestyle diseases (diabetes, cardiac, respiratory)
  • Hospital construction boom (new multi-specialty hospitals)
  • Government health initiatives (Ayushman Bharat)

This growth is sustainable for 5-10+ years.

Why Novalab Critical Care Beats 30+ Competitors in Delhi

Head-to-Head Comparison:

Factor Novalab Critical Care Generic Competitors
Product Specialization ICU-only focus, 150+ injectables General pharma mix, 50-80 SKUs
Profit Margins 30-50% (critical care premium) 15-25% (lower margins)
Monopoly Rights Written, guaranteed territory Often vague, internal competition
Hospital Support Tender assistance, procurement strategy No hospital-specific support
Logistics Speed 2-3 day delivery (critical care) 7-14 days (slow)
Training Comprehensive ICU protocols Generic product training only
Account Management Dedicated territory manager Email-based support only
Emergency Support 24/7 logistics for time-critical orders Business hours only
Franchisee Community 200+ active partners (peer network) No community support

Your Action Plan: Delhi Critical Care Success Checklist

Week 1-2: Foundation Phase

  • Map 20+ hospitals in preferred Delhi zone
  • Visit nursing homes + diagnostic centers
  • Collect hospital procurement manager contacts
  • Gather market intelligence on current suppliers

Week 2-3: Legal Phase

  • Apply for Drug License (Delhi Drug Authority)
  • Register for GST (online)
  • Prepare business registration documents
  • Gather address proof

Week 3-4: Franchise Application Phase

  • Contact Novalab Critical Care
  • Submit franchise application (territory preference)
  • Share hospital contact list you’ve developed
  • Download + review franchise agreement

Week 4-5: Agreement Phase

  • Review monopoly clause + territory definition
  • Finalize payment terms
  • Sign agreement + make first payment
  • Get account manager assigned

Week 5-6: Training & Stock Phase

  • Attend product training (ICU injectables)
  • Receive initial stock (2-3 days)
  • Set up home office/storage
  • Prepare hospital detailing materials

Week 7 onwards: Launch Phase

  • Begin hospital procurement manager outreach (2-3 per day)
  • Distribute samples + clinical information
  • Submit tender proposals for regular supply
  • Track first hospital order (expected week 4-6)

Your Next Steps: Start Your ICU Medicines PCD Franchise in Delhi Today

Ready to Build Delhi’s Most Profitable Critical Care Business?

Step 1: Visit https://www.novalabcriticalcare.com/

Step 2: Select “ICU Medicines PCD Franchise” + Choose Delhi territory

Step 3: Download franchise brochure & identify hospitals in your zone

Step 4: Contact Novalab Critical Care Franchise Team:

Step 5: Schedule 30-minute consultation to discuss:

  • Your preferred Delhi zone (South, East, North, NCR)
  • Hospital network you’ve identified
  • Investment options (₹75K-₹2.5L)
  • Profit potential (₹2+ lakh monthly)

Why 2026 is Your Year to Enter Delhi’s Critical Care Market

Delhi’s ICU medicines market is at peak growth inflection. Post-pandemic infrastructure expansion, aging population, and lifestyle diseases create constant, life-saving demand for premium injectables.

Franchisees entering Delhi’s critical care market in 2026 will build ₹2-4 lakh monthly businesses within 12 months. With Novalab Critical Care‘s specialized injectable portfolio + hospital support + monopoly protection, you’re not just starting a business—you’re entering India’s most profitable pharma segment.

Don’t wait. Your ₹2-3 lakh monthly ICU franchise is waiting. Go live now. 🚀

Nova Lab Critical Care – Footer